Puma Biotechnology Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $231.2M+0.3% YoYTTM through 30 Jun 2026
Net Income $26.7M-11.8% YoYTTM through 30 Jun 2026
Free Cash Flow $41.1MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 74.5% |
| EBITDA Margin | 17.7% |
| Operating Margin | 16.3% |
| Net Margin | 11.6% |
Returns
23.9%ROE
14.4%ROA
26.2%ROIC
Balance Sheet Health
Debt / Equity0.17x
Current Ratio2.91x
Net Debt-$75Mnet cash position
Cash & Equivalents$36.5M
Quality Metrics
Altman Z-Score-1.37
Piotroski F-Score5 / 9
FCF Margin17.8%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $228.4M
Diluted EPS$0.51TTMFY2025: $0.61
Dividend
No dividend
Capital Allocation
Capex Intensity-4,324.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| NERLYNX Product Sales | $204.1M | +4.6% | |
| Royalty Revenue | $24.3M | -31.2% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.